The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche; Sysmex
Consulting or Advisory Role - Genentech; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical
 
Lauren Brusco
No Relationships to Disclose
 
Molly S Daniels
No Relationships to Disclose
 
Louise C. Strong
No Relationships to Disclose
 
Kenna Rael Shaw
No Relationships to Disclose
 
Karen H. Lu
No Relationships to Disclose
 
Yuan Qi
No Relationships to Disclose
 
Humberto Lara-Guerra
No Relationships to Disclose
 
Jennifer Keating Litton
Research Funding - Biomarin (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Biomarin; Novartis
 
Hao Zhao
No Relationships to Disclose
 
Agda Karina Eterovic
No Relationships to Disclose
 
Banu Arun
Research Funding - Avon Foundation; NCI; NCI, Susan G. Komen, Avon; Susan G. Komen for the Cure
 
Mark Routbort
Travel, Accommodations, Expenses - Oracle Corporation
 
Filip Janku
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Scott Kopetz
Consulting or Advisory Role - Agendia; Amgen; Array BioPharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merrimack; Roche; Sanofi; Sysmex; Taiho Pharmaceutical
Research Funding - Agendia; Amgen; Biocartis; GlaxoSmithKline; Guardant Health; Roche; Sanofi; Sysmex
 
John Mendelsohn
Leadership - Merrimack
Consulting or Advisory Role - Capital Royalty
Patents, Royalties, Other Intellectual Property - University of California at San Diego/Imclone
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; PTV Sciences; Spindletop Ventures
Consulting or Advisory Role - AstraZeneca; Blend Therapeutics; Critical Outcome Technologies; HanAl Bio Korea; Illumina; Nuevolution; Pfizer; Provista Diagnostics; Roche Pharma AG; SignalChem; Symphony Evolution; Tau Therapeutics
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Critical Outcome Technologies; GlaxoSmithKline; Illumina
Patents, Royalties, Other Intellectual Property - Cytovia Inc; Millennium
Travel, Accommodations, Expenses - AstraZeneca; Illumina; Nuevolution; Symphony Evolution
 
Ken Chen
No Relationships to Disclose